A method for detecting hand, foot and mouth disease based on CRISPR technology

Through CRISPR technology, using CRISPR/CAS effector protein, gRNA and single-stranded nucleic acid detector, the complex and time-consuming problems of existing hand, foot and mouth disease detection methods are solved, and the rapid and simple viral nucleic acid detection is achieved, satisfying the opponent's foot and mouth The need for rapid diagnosis of disease viruses.

CN114058735BActive Publication Date: 2024-11-26SHANDONG SHUNFENG BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202010771023.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-08-03
Publication Date
2024-11-26
Estimated Expiration
2040-08-03

AI Technical Summary

Technical Problem

Existing methods for detecting hand, foot and mouth disease such as qPCR take a long time, complex equipment and high operating requirements, and cannot meet the needs of fast and simple testing.

Method used

Using CRISPR technology, the V-type or VI type CRISPR/CAS effector protein, gRNA and single-stranded nucleic acid detector are used to bind to the CRISPR/CAS effector protein by targeting the viral nucleic acid guide sequence to cleave the single-stranded nucleic acid detector to produce the single-stranded nucleic acid detector. signal, thus enabling rapid detection.

Benefits of technology

It realizes rapid, simple and specific detection of hand, foot and mouth disease viruses, reduces equipment and operation complexity, and improves detection efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002615985500000171
    Figure BDA0002615985500000171
  • Figure BDA0002615985500000172
    Figure BDA0002615985500000172
  • Figure HDA0002615985510000011
    Figure HDA0002615985510000011
Patent Text Reader

Abstract

The present invention provides a method for detecting hand, foot and mouth disease based on CRISPR technology, comprising the steps of detecting using gRNA, Cas protein and a single-stranded nucleic acid detector, wherein the single-stranded nucleic acid detector can be single-stranded DNA, single-stranded RNA or a single-stranded DNA-RNA hybrid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of nucleic acid detection, and in particular to a method, system and kit for detecting hand, foot and mouth disease based on CRISPR technology. Background Art

[0002] Hand, foot and mouth disease (HFMD) is a common childhood infectious disease caused by enterovirus infection, which is common in children under 5 years old. HFMD is a global disease that occurs throughout the year in various parts of my country, with an incidence rate of 37.01 / 100,000 to 205.06 / 100,000. In recent years, the case fatality rate has been reported to be between 6.46 / 100,000 and 51.00 / 100,000. Enterovirus belongs to the genus Enterovirus of the family Picornaviridae. HFMD is caused by enterovirus, and the main pathogenic serotypes include Coxsackievirus (CV) A group 4-7, 9, 10, 16 and B group 1-3, 5, some serotypes of echovirus, and enterovirus 71 (Enterovirus A71, EV-A71, or EV 71), among which CV-A16 and EV-A71 are the most common, and severe and fatal cases are mostly caused by EV-A71.

[0003] At present, clinical testing is still mainly based on qPCR, but qPCR takes too long (2 hours), requires complex instruments and equipment, and has high requirements on the proficiency and professionalism of operators. The recently emerging isothermal amplification technology LAMP / RPA can amplify target fragments efficiently, specifically, and quickly under constant temperature conditions (the reaction temperature of LAMP is 65°C, and the reaction temperature of RPA is 37°C), and does not require complex instruments and equipment. Summary of the invention

[0004] The present invention provides a method, system and kit for detecting target nucleic acid based on CRISPR technology.

[0005] On the one hand, the present invention provides a method for detecting a target nucleic acid in a sample, the method comprising contacting the sample with a type V or type VI CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector, the gRNA comprising a region binding to the CRISPR / CAS effector protein and a guide sequence hybridizing with the target nucleic acid; detecting a detectable signal generated by the CRISPR / CAS effector protein cutting the single-stranded nucleic acid detector, thereby detecting the target nucleic acid; the target nucleic acid is a viral nucleic acid, and the virus can cause hand, foot and mouth disease.

[0006] On the other hand, the present invention also provides a system or composition for detecting target nucleic acids in a sample, the system or composition comprising a type V or type VI CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector, the gRNA comprising a region binding to the CRISPR / CAS effector protein and a guide sequence hybridizing with the target nucleic acid; the target nucleic acid is the nucleic acid of a virus that causes hand, foot and mouth disease.

[0007] On the other hand, the present invention also provides a kit for detecting target nucleic acid in a sample, the kit comprising a type V or type VI CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector, the gRNA comprising a region binding to the CRISPR / CAS effector protein and a guide sequence hybridizing with the target nucleic acid; the target nucleic acid is a viral nucleic acid, and the virus can cause hand, foot and mouth disease.

[0008] On the other hand, the present invention also provides the use of the above-mentioned system or kit in detecting target nucleic acid in a sample; the target nucleic acid is a viral nucleic acid, and the virus can cause hand, foot and mouth disease.

[0009] On the other hand, the present invention also provides the use of type V or type VI CRISPR / CAS effector protein in detecting target nucleic acid in a sample; the target nucleic acid is a viral nucleic acid, and the virus can cause hand, foot and mouth disease.

[0010] As described above, the V-type or VI-type CRISPR / CAS effector protein can cut the single-stranded nucleic acid detector in the system after binding or hybridizing with the target nucleic acid in the sample.

[0011] On the other hand, the present invention also provides the use of type V or type VI CRISPR / CAS effector protein in preparing a reagent for detecting a target nucleic acid in a sample; the target nucleic acid is a viral nucleic acid, and the virus can cause hand, foot and mouth disease.

[0012] On the other hand, the present invention also provides a system or composition or kit for diagnosing and / or detecting hand, foot and mouth disease, the system or composition or kit comprising the above-mentioned type V or type VI CRISPR / CAS effector protein, gRNA and single-stranded nucleic acid detector; the gRNA comprises a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the nucleic acid of the virus that causes hand, foot and mouth disease. In a preferred embodiment, the system or composition or kit also includes primers for amplifying viral nucleic acids; preferably, the primers are LAMP primers, and preferably, the primer set used for LAMP is shown in SEQ ID NO: 1-6.

[0013] In one embodiment, the target nucleic acid is an enterovirus nucleic acid. Preferably, the enterovirus is selected from one or any combination of Coxsackievirus A group 4, Coxsackievirus A group 5, Coxsackievirus A group 6, Coxsackievirus A group 7, Coxsackievirus A group 9, Coxsackievirus A group 10, Coxsackievirus A group 16, Coxsackievirus B group 1, Coxsackievirus B group 2, Coxsackievirus B group 3, Coxsackievirus B group 5, and enterovirus 71 (EV 71); more preferably, the enterovirus is enterovirus 71 (EV 71).

[0014] On the other hand, the present invention also provides a method for diagnosing and / or detecting hand, foot and mouth disease, the method comprising contacting the nucleic acid to be tested with a type V or type VI CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector, the gRNA comprising a region binding to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the nucleic acid of a virus that causes hand, foot and mouth disease; detecting a detectable signal generated by the CRISPR / CAS effector protein cutting the single-stranded nucleic acid detector, thereby diagnosing and / or detecting hand, foot and mouth disease.

[0015] Furthermore, the method also includes the step of obtaining the nucleic acid to be tested from the sample to be tested; preferably, the nucleic acid to be tested is obtained from the sample to be tested by an amplification method.

[0016] The amplification of the present invention is selected from one or any of PCR, nucleic acid sequencing-based amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), helicase-dependent amplification (HDA), or nickase amplification reaction (NEAR), multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR), or derivative amplification method (RAM). In a preferred embodiment, the amplification is LAMP.

[0017] In a preferred embodiment, the primer set used in the LAMP is shown as SEQ ID NO: 1-6.

[0018] In the present invention, the sample can be a sample from a subject, including but not limited to a throat swab, blood, sputum, bronchoalveolar lavage fluid sample, cerebrospinal fluid, herpes fluid and anal swab of the subject.

[0019] On the other hand, the present invention also provides a kit for detecting or diagnosing whether a subject is infected with hand, foot and mouth disease virus, the kit comprising the above-mentioned type V or type VI CRISPR / CAS effector protein, gRNA (guide RNA) and a single-stranded nucleic acid detector; the gRNA comprises a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the hand, foot and mouth disease virus nucleic acid. In a preferred embodiment, the kit also includes primers for amplifying hand, foot and mouth disease virus; preferably, the primers are LAMP primers, and preferably, the primer set used for LAMP is shown in SEQ ID NO: 1-6.

[0020] On the other hand, the present invention also provides a LAMP primer set for amplifying or detecting enterovirus 71 (EV 71), the primer set comprising primers EV71-FIP, EV71-BIP, EV71-F3, EV71-B3, EV71-LF and EV71-LR; the sequences of the primers EV71-FIP, EV71-BIP, EV71-F3, EV71-B3, EV71-LF and EV71-LR are shown in SEQ ID NOs: 1-6, respectively.

[0021] On the other hand, the present invention also provides the use of the above-mentioned LAMP primer set in detecting or diagnosing hand, foot and mouth disease.

[0022] On the other hand, the present invention also provides the use of the above-mentioned LAMP primer set in preparing a reagent or a kit for detecting or diagnosing hand, foot and mouth disease.

[0023] On the other hand, the present invention also provides a kit for detecting hand, foot and mouth disease, which includes the above-mentioned LAMP primer set; preferably, the kit also includes the above-mentioned V-type or VI-type Cas protein, gRNA and single-stranded nucleic acid detector.

[0024] The hand, foot and mouth disease described in the present invention may be hand, foot and mouth disease caused by one or any combination of coxsackievirus A group 4, coxsackievirus A group 5, coxsackievirus A group 6, coxsackievirus A group 7, coxsackievirus A group 9, coxsackievirus A group 10, coxsackievirus A group 16, coxsackievirus B group 1, coxsackievirus B group 2, coxsackievirus B group 3, coxsackievirus B group 5, and enterovirus 71 (EV 71); preferably, it is hand, foot and mouth disease caused by enterovirus 71 (EV 71).

[0025] Furthermore, the V-type CRISPR / CAS effector protein is selected from Cas12, Cas14 family proteins or mutants thereof, and the VI-type CRISPR / CAS effector protein includes Cas13 family proteins or mutants thereof.

[0026] In one embodiment, the Cas protein is preferably a Cas12 family, including but not limited to one or any several of Cas12a, Cas12b, Cas12d, Cas12e, Cas12f, Cas12g, Cas12h, Cas12i, and Cas12j.

[0027] In one embodiment, the Cas12a is selected from one or any several of FnCas12a, AsCas12a, LbCas12a, Lb5Cas12a, HkCas12a, OsCas12a, TsCas12a, BbCas12a, BoCas12a or Lb4Cas12a; the Cas12a is preferably LbCas12a, and the amino acid sequence is as shown in SEQ ID No.7, or the amino acid sequence shown in SEQ ID No.7 or its active fragment is substituted, deleted or added with one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues, and has a derivative protein with substantially the same function.

[0028] In other embodiments, the amino acid sequence of Cas12b is as shown in SEQ ID No.8, or the amino acid sequence shown in SEQ ID No.8 or its active fragment is replaced, deleted or added with one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues, and a derivative protein with substantially the same function is formed.

[0029] In one embodiment, the Cas13 family protein includes Cas13a and Cas13b, and preferably, the Cas13a is selected from Lshcas13a.

[0030] In a preferred embodiment, the amino acid sequence of the Cas12i protein is selected from the group consisting of:

[0031] (1) the protein shown in SEQ ID NO: 9;

[0032] (2) A derivative protein having substantially the same function as the amino acid sequence shown in SEQ ID NO: 9 or an active fragment thereof, which is formed by substitution, deletion or addition of one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues.

[0033] The amino acid sequence of the Cas12j protein is selected from the group consisting of:

[0034] (1) the protein shown in SEQ ID NO: 10;

[0035] (2) A derivative protein having substantially the same function as the amino acid sequence shown in SEQ ID NO: 10 or an active fragment thereof, which is formed by substitution, deletion or addition of one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues.

[0036] In one embodiment, the Cas protein mutant comprises an amino acid substitution, deletion or replacement, and the mutant at least retains its trans cleavage activity. Preferably, the mutant has Cis and trans cleavage activity.

[0037] In the present invention, the target nucleic acid includes ribonucleotides or deoxyribonucleotides, including single-stranded nucleic acids and double-stranded nucleic acids, such as single-stranded DNA, double-stranded DNA, single-stranded RNA, and double-stranded RNA.

[0038] In the present invention, the single-stranded nucleic acid detector includes single-stranded DNA, single-stranded RNA or single-stranded DNA-RNA hybrid. In other embodiments, the single-stranded nucleic acid detector includes a mixture of any two or three of single-stranded DNA, single-stranded RNA or single-stranded DNA-RNA hybrid, for example, a combination of single-stranded DNA and single-stranded RNA, a combination of single-stranded DNA and single-stranded DNA-RNA hybrid, and a combination of single-stranded RNA and single-stranded DNA-RNA. In other embodiments, the single-stranded nucleic acid detector also includes a modification of the base.

[0039] In a preferred embodiment, the single-stranded nucleic acid detector is a single-stranded oligonucleic acid detector.

[0040] The single-stranded nucleic acid detector does not hybridize with the gRNA.

[0041] In the present invention, the detectable signal is achieved by the following means: vision-based detection, sensor-based detection, color detection, gold nanoparticle-based detection, fluorescence polarization, colloidal phase transition / dispersion, electrochemical detection and semiconductor-based detection.

[0042] In some embodiments, the method of the present invention further comprises the step of measuring a detectable signal generated by a CRISPR / CAS effector protein (Cas protein). After the Cas protein recognizes the target nucleic acid or hybridizes with the target nucleic acid, it can stimulate the cleavage activity of the single-stranded nucleic acid, thereby cleaving the single-stranded nucleic acid detector and generating a detectable signal.

[0043] In the present invention, the detectable signal can be any signal generated when the single-stranded nucleic acid detector is cut. For example, detection based on gold nanoparticles, fluorescence polarization, colloidal phase change / dispersion, electrochemical detection, semiconductor-based sensing. The detectable signal can be read out by any suitable means, including but not limited to: measurement of detectable fluorescent signals, gel electrophoresis detection (by detecting changes in bands on the gel), detection of the presence or absence of color based on vision or sensors, or differences in the presence of colors (e.g., based on gold nanoparticles) and differences in electrical signals.

[0044] In a preferred embodiment, the detectable signal is achieved in the following manner: different reporter groups are respectively set at the 5' end and the 3' end of the single-stranded nucleic acid detector, and when the single-stranded nucleic acid detector is cut, a detectable reporter signal can be exhibited; for example, a fluorescent group and a quenching group are respectively set at the two ends of the single-stranded nucleic acid detector, and when the single-stranded nucleic acid detector is cut, a detectable fluorescent signal can be exhibited.

[0045] In one embodiment, the fluorescent group is selected from one or any several of FAM, FITC, VIC, JOE, TET, CY3, CY5, ROX, Texas Red or LC RED460; the quenching group is selected from one or any several of BHQ1, BHQ2, BHQ3, Dabcy1 or Tamra.

[0046] In other embodiments, the detectable signal can also be achieved in the following manner: different labeling molecules are respectively provided at the 5' end and the 3' end of the single-stranded nucleic acid detector, and the reaction signal is detected by colloidal gold detection.

[0047] In one embodiment, the target nucleic acid includes DNA, RNA, preferably single-stranded nucleic acid or double-stranded nucleic acid or nucleic acid modification.

[0048] In some embodiments, the measurement of the detectable signal can be quantitative, and in other embodiments, the measurement of the detectable signal can be qualitative.

[0049] Preferably, the single-stranded nucleic acid detector generates a first detectable signal before being cleaved by the Cas protein, and generates a second detectable signal different from the first detectable signal after being cleaved.

[0050] In other embodiments, the single-stranded nucleic acid detector includes one or more modifications, such as base modifications, backbone modifications, sugar modifications, etc., to provide new or enhanced features (such as improved stability) to the nucleic acid. Examples of suitable modifications include modified nucleic acid backbones and non-natural internucleoside linkages, and nucleic acids with modified backbones include those that retain phosphorus atoms in the backbone and those that do not have phosphorus atoms in the backbone. Suitable modified oligonucleotide backbones containing phosphorus atoms include phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkylphosphonates. In some embodiments, the single-stranded nucleic acid detector contains one or more phosphorothioates and / or heteroatom nucleoside bonds. In other embodiments, the single-stranded nucleic acid detector can be a nucleic acid mimetic; in certain embodiments, the nucleic acid mimetic is a peptide nucleic acid (PNA), another type of nucleic acid mimetic is based on a linked morpholinyl unit (morpholinyl nucleic acid) having a heterocyclic base attached to a morpholine ring, and other nucleic acid mimics also include cyclohexenyl nucleic acids (CENA), and also include ribose or deoxyribose chains.

[0051] In the present invention, the gRNA includes a sequence targeting the target nucleic acid (guide sequence) and a sequence recognizing the Cas protein (a direct repeat sequence or a portion thereof).

[0052] In the present invention, the guide sequence comprises 10-40 bp; preferably, 12-25 bp; preferably, 15-23 bp; preferably, 16-18 bp.

[0053] In the present invention, the gRNA has at least 50% matching degree with the characteristic sequence to be detected, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%.

[0054] In one embodiment, the detection method may include one or more gRNAs with different guide sequences, which target different characteristic sequences.

[0055] In one embodiment, the identifying of the characteristic sequence to be detected includes binding and / or cutting the characteristic sequence to be detected.

[0056] In one embodiment, the molar ratio of the Cas protein to the gRNA is (0.8-1.2):1.

[0057] In one embodiment, the final concentration of the Cas protein is 20-200 nM, preferably, 30-100 nM, more preferably, 40-80 nM, more preferably, 50 nM.

[0058] In one embodiment, the final concentration of the gRNA is 20-200 nM, preferably, 30-100 nM, more preferably, 40-80 nM, more preferably, 50 nM.

[0059] In one embodiment, the target nucleic acid is used at a final concentration of 5-100 nM, preferably, 10-50 nM.

[0060] In one embodiment, the single-stranded nucleic acid detector is used at a final concentration of 100-1000 nM, preferably 150-800 nM, preferably 200-800 nM, preferably 200-500 nM, preferably 200-300 nM.

[0061] In one embodiment, the single-stranded nucleic acid detector has 2-300 nucleotides, preferably 3-200 nucleotides, preferably 3-100 nucleotides, preferably 3-30 nucleotides, preferably 4-20 nucleotides, more preferably 5-15 nucleotides.

[0062] In one embodiment, the method can be used for quantitative detection of characteristic sequences to be detected.

[0063] The term "hybridization" or "complementary" or "substantially complementary" refers to a nucleic acid (e.g., RNA, DNA) comprising a nucleotide sequence that enables it to non-covalently bind, i.e., to form base pairs and / or G / U base pairs, "anneal" or "hybridize" with another nucleic acid in a sequence-specific, antiparallel manner (i.e., nucleic acid-specific binding to complementary nucleic acids). Hybridization requires that the two nucleic acids contain complementary sequences, although there may be mismatches between the bases. Suitable conditions for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementarity, which are variables well known in the art. Typically, the length of a hybridizable nucleic acid is 8 nucleotides or more (e.g., 10 nucleotides or more, 12 nucleotides or more, 15 nucleotides or more, 20 nucleotides or more, 22 nucleotides or more, 25 nucleotides or more, or 30 nucleotides or more).

[0064] It should be understood that the sequence of a polynucleotide need not be 100% complementary to the sequence of its target nucleic acid to specifically hybridize. A polynucleotide may comprise 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence complementarity to the target region in the target nucleic acid sequence with which it hybridizes.

[0065] The present invention finds that once a V-type or VI-type CRISPR / CAS protein (including Cas12i, Cas12j, Cas12a, Cas12b, Cas13a) is activated by binding to a target nucleic acid, it can promiscuously cut non-targeted single-stranded DNA (ssDNA), single-stranded RNA (ssRNA) or single-stranded DNA-RNA hybrids. Therefore, when the target nucleic acid is present in a sample, the CRISPR / CAS protein can be used to cut a single-stranded nucleic acid detector (including single-stranded DNA, single-stranded RNA or single-stranded DNA-RNA hybrid), and the detection signal exhibited by the single-stranded nucleic acid detector is detected.

[0066] General Definition:

[0067] Unless defined otherwise, technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0068] The term "amino acid" refers to a carboxylic acid containing an amino group. Various proteins in living organisms are composed of 20 basic amino acids.

[0069] The terms "polynucleotide", "nucleotide sequence", "nucleic acid sequence", "nucleic acid molecule" and "nucleic acid" are used interchangeably and include DNA, RNA or hybrids thereof, which may be double-stranded or single-stranded.

[0070] The term "oligonucleotide" refers to a sequence containing 3-100 nucleotides, preferably, 3-30 nucleotides, preferably, 4-20 nucleotides, more preferably, 5-15 nucleotides.

[0071] The terms "homology" or "identity" are used to refer to the match between the sequences of two polypeptides or two nucleic acids.

[0072] When the subunits are occupied (for example, a position in each of the two DNA molecules is occupied by adenine,

[0073] or a position in each of the two polypeptides is occupied by lysine, then each molecule has

[0074] is identical. Between two sequences. Usually, when two sequences are aligned to produce maximum identity

[0075] Comparison. Such an alignment can be determined by using, for example, the identity of the amino acid sequence can be determined by conventional methods, with reference to, for example, Smith and Waterman, 1981, Adv. Appl. Math. 2: 482 Pearson & Lipman, 1988, Proc. Natl Acad. Sci. USA 85: 2444, Thompson et al., 1994, Nucleic Acids Res 22: 467 380, etc., by computerized operation of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group). It can also be determined using the BLAST algorithm available from the National Center for Biotechnology Information (NCBI www.ncbi.nlm.nih.gov / ) using default parameters.

[0076] As used herein, the "CRISPR" refers to Clustered regularly interspaced short palindromic repeats, which are derived from the immune system of microorganisms.

[0077] As used herein, "biotin", also known as vitamin H, is a small molecule vitamin with a molecular weight of 244 Da. "Avidin", also known as anti-biotin, is an alkaline glycoprotein with 4 binding sites with extremely high affinity to biotin. Commonly used avidins include streptavidin. The extremely strong affinity of biotin and avidin can be used to amplify or enhance the detection signal in the detection system. For example, biotin can easily bind to proteins (such as antibodies, etc.) with covalent bonds, and the avidin molecules bound to the enzyme react with the biotin molecules bound to the specific antibody, which not only plays a multi-stage amplification role, but also produces color due to the catalytic effect of the enzyme when it encounters the corresponding substrate, thereby achieving the purpose of detecting unknown antigen (or antibody) molecules.

[0078] LAMP

[0079] LAMP is also known as the loop-mediated isothermal amplification (LAMP) method (WO00 / 28082). The LAMP method was developed by Notomi et al. and can be performed at a constant temperature. In this method, the 3' end of the template nucleotide is annealed, and the complementary chain is synthesized from there, and a primer that anneals to the loop formed by the above synthesis is used in combination. This allows nucleic acid amplification to be performed under isothermal conditions. In the LAMP method, the 3' end of the primer is always annealed to a region derived from the sample, and thus, a mechanism for verifying complementary bonding of nucleotide sequences is repeatedly activated. As a result, highly sensitive and specific nucleic acid amplification is achieved.

[0080] Hand, foot and mouth disease

[0081] Hand, foot and mouth disease is caused by enterovirus, mainly including Coxsackievirus (CV) A group 4-7, 9, 10, 16 and B group 1-3, 5, some serotypes of Echovirus and enterovirus 71 (Enterovirus A71, EV-A71, or EV 71), among which CV-A16 and EV-A71 are the most common, and severe and fatal cases are mostly caused by EV-A71. Preferably, in the present invention, detecting hand, foot and mouth disease refers to detecting enterovirus 71 (Enterovirus A71, EV-A71, or EV 71).

[0082] Cas proteins

[0083] The "Cas protein" described herein refers to a CRISPR-associated protein, preferably a CRISPR / CAS protein from type V or type VI, which, once bound to a characteristic sequence (target sequence) to be detected (i.e., forming a ternary complex of Cas protein-gRNA-target sequence), can induce its trans activity, i.e., randomly cutting non-targeted single-stranded nucleotides (i.e., the single-stranded nucleic acid detector described herein, preferably single-stranded DNA (ssDNA), single-stranded DNA-RNA hybrid, single-stranded RNA). When the Cas protein binds to a characteristic sequence, it can induce its trans activity by cutting or not cutting the characteristic sequence; preferably, it induces its trans activity by cutting the characteristic sequence; more preferably, it induces its trans activity by cutting the single-stranded characteristic sequence.

[0084] The Cas protein described in the present invention is a protein having at least trans cleavage activity, preferably, the Cas protein is a protein having Cis and trans cleavage activity. The Cis activity refers to the activity of the Cas protein in recognizing the PAM site and specifically cleaving the target sequence under the action of gRNA.

[0085] The Cas protein of the present invention includes type V and type VI CRISPR / CAS effector proteins, including protein families such as Cas12, Cas13, and Cas14. Preferably, for example, Cas12 protein, such as Cas12a, Cas12b, Cas12d, Cas12e, Cas12f, Cas12g, Cas12h, Cas12i, and Cas12j; preferably, the Cas protein is Cas12a, Cas12b, Cas12i, and Cas12j. The Cas13 protein family includes Cas13a, Cas13b, and the like.

[0086] In an embodiment, the Cas protein referred to herein, such as Cas12, also encompasses functional variants of Cas or its homologs or orthologs. As used herein, the "functional variant" of a protein refers to a variant of such a protein that at least partially retains the activity of the protein. Functional variants may include mutants (which may be insertion, deletion or substitution mutants), including polymorphs, etc. Functional variants also include fusion products of such a protein with another generally unrelated nucleic acid, protein, polypeptide or peptide. Functional variants may be naturally occurring or may be artificial. Favorable embodiments may relate to engineered or non-naturally occurring V-type DNA targeting effector proteins.

[0087] In one embodiment, one or more nucleic acid molecules encoding a Cas protein, such as Cas12, or its orthologs or homologs can be codon optimized for expression in eukaryotic cells. Eukaryotic organisms can be as described herein. One or more nucleic acid molecules can be engineered or non-naturally occurring.

[0088] In one embodiment, the Cas12 protein or its ortholog or homolog may comprise one or more mutations (and thus the nucleic acid molecule encoding it may have one or more mutations. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain.

[0089] In one embodiment, the Cas protein can be from: Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Azospirillum, Sphaerochaeta, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, Campylobacter, and Lachnospira.

[0090] In one embodiment, the Cas protein is selected from the group consisting of the following sequences:

[0091] (1) proteins shown in SEQ ID NOs: 7-10;

[0092] (2) Derivative proteins having substantially the same function as the amino acid sequence shown in SEQ ID NO: 7-10 or its active fragments formed by substitution, deletion or addition of one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues.

[0093] In one embodiment, the Cas protein also includes a protein having 50%, preferably 55%, preferably 60%, preferably 65%, preferably 70%, preferably 75%, preferably 80%, preferably 85%, preferably 90%, preferably 95% sequence identity with the above sequence and having trans activity.

[0094] The Cas protein can be obtained by recombinant expression vector technology, that is, the nucleic acid molecule encoding the protein is constructed into a suitable vector, and then transformed into a host cell, so that the encoding nucleic acid molecule is expressed in the cell, thereby obtaining the corresponding protein. The protein can be secreted by the cell, or the cell can be cracked to obtain the protein by conventional extraction techniques. The encoding nucleic acid molecule can be integrated into the genome of the host cell for expression, or it can be expressed without being integrated into the host cell. The vector further includes regulatory elements that are conducive to sequence integration or self-replication. The vector can be a plasmid, a virus, a cosmid, a phage, etc., which are well known to those skilled in the art. Preferably, the expression vector in the present invention is a plasmid. The vector further includes one or more regulatory elements selected from promoters, enhancers, ribosome binding sites for translation initiation, terminators, polyadenylic acid sequences, and selection marker genes.

[0095] The host cell can be a prokaryotic cell, such as Escherichia coli, Streptomyces, Agrobacterium; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a plant cell. Those skilled in the art are aware of how to select appropriate vectors and host cells.

[0096] gRNA

[0097] As used herein, the "gRNA" is also referred to as guide RNA or guide RNA, and has the meaning generally understood by those skilled in the art. In general, the guide RNA may include a direct repeat sequence and a guide sequence, or may consist essentially of or consist of a direct repeat sequence and a guide sequence (also referred to as a spacer in the context of an endogenous CRISPR system). In different CRISPR systems, gRNA may include crRNA and tracrRNA, or may only contain crRNA, depending on the different Cas proteins on which it depends. CrRNA and tracrRNA may be artificially modified and fused to form a single guide RNA (sgRNA). In some cases, the guide sequence is any polynucleotide sequence that has sufficient complementarity with the target sequence (the characteristic sequence described in the present invention) to hybridize with the target sequence and guide the specific binding of the CRISPR / Cas complex to the target sequence, typically having a sequence length of 12-25nt. The direct repeat sequence may be folded to form a specific structure (such as a stem-loop structure) for recognition by the Cas protein to form a complex. The guide sequence does not need to be 100% complementary to the characteristic sequence (target sequence). The guide sequence is not complementary to the single-stranded nucleic acid detector.

[0098] In certain embodiments, when optimally aligned, the degree of complementarity (match) between a guide sequence and its corresponding target sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. Determining optimal alignment is within the capabilities of one of ordinary skill in the art. For example, there are publicly available and commercially available alignment algorithms and programs, such as, but not limited to, ClustalW, Smith-Waterman in matlab, Bowtie, Geneious, Biopython, and SeqMan.

[0099] The gRNA described in the present invention may be natural, or artificially modified or designed and synthesized.

[0100] Single-stranded nucleic acid detector

[0101] The single-stranded nucleic acid detector of the present invention refers to a sequence containing 2-200 nucleotides, preferably 2-150 nucleotides, preferably 3-100 nucleotides, preferably 3-30 nucleotides, preferably 4-20 nucleotides, more preferably 5-15 nucleotides, preferably a single-stranded DNA molecule, a single-stranded RNA molecule or a single-stranded DNA-RNA hybrid.

[0102] The single-stranded nucleic acid detector is used in the detection method or system to report whether the target nucleic acid exists in the sample. The single-stranded nucleic acid detector includes different reporting groups or labeling molecules at both ends. When it is in the initial state (i.e., uncleaved state), it does not present a reporting signal. When the single-stranded nucleic acid detector is cleaved, it presents a detectable signal, i.e., a detectable difference is shown after cleavage and before cleavage. In the present invention, if a detectable difference can be detected, it reflects that the target nucleic acid can be detected; or, if the detectable difference cannot be detected, it reflects that the target nucleic acid cannot be detected.

[0103] In one embodiment, the reporter group or labeling molecule includes a fluorescent group and a quencher group, the fluorescent group is selected from one or any several of FAM, FITC, VIC, JOE, TET, CY3, CY5, ROX, Texas Red or LC RED460; the quencher group is selected from one or any several of BHQ1, BHQ2, BHQ3, Dabcy1 or Tamra.

[0104] In other embodiments, the single-stranded nucleic acid detector has a first molecule (such as FAM or FITC) connected to one end and a second molecule (such as biotin) connected to the other end. The reaction system containing the single-stranded nucleic acid detector is used in conjunction with a flow strip to detect target nucleic acids (preferably, colloidal gold detection). The flow strip is designed to have two capture lines, with an antibody that binds to the first molecule (i.e., the first molecule antibody) at the sample contact end (colloidal gold), an antibody that binds to the first molecule antibody at the first line (control line), and an antibody that binds to the second molecule (i.e., the second molecule antibody, such as avidin) at the second line (test line). When the reaction flows along the strip, the first molecule antibody binds to the first molecule and carries the cut or uncut oligonucleotide to the capture line, and the cut reporter will bind to the antibody of the first molecule antibody at the first capture line, and the uncut reporter will bind to the second molecule antibody at the second capture line. The binding of the reporter group to each line will result in a strong readout / signal (e.g., color). As more reporters are cut, more signals will accumulate at the first capture line, and less signals will appear at the second line. In some aspects, the present invention relates to the use of a flow strip as described herein for detecting nucleic acids. In some aspects, the present invention relates to a method for detecting nucleic acids using a flow strip as defined herein, such as a (lateral) flow test or a (lateral) flow immunochromatographic assay. In some aspects, the molecules in the single-stranded nucleic acid detector can be replaced with each other, or the position of the molecules can be changed, as long as the reporting principle is the same or similar to the present invention, the improved method is also included in the present invention.

[0105] The detection method of the present invention can be used for quantitative detection of target nucleic acid. The quantitative detection index can be quantified according to the signal strength of the reporter group, such as according to the luminescence intensity of the fluorescent group, or according to the width of the color band.

[0106] Sequence information

[0107] The partial sequence information involved in the present invention is provided as follows:

[0108] Serial number describe type SEQ ID NO: 1 EV71-FIP DNA SEQ ID NO: 2 EV71-BIP DNA SEQ ID NO: 3 EV71-F3 DNA SEQ ID NO: 4 EV71-B3 DNA SEQ ID NO: 5 EV71-LF DNA SEQ ID NO: 6 EV71-LR DNA SEQ ID NO: 7 LbCas12a Protein SEQ ID NO: 8 Cas12b Protein SEQ ID NO: 9 Cas12i Protein SEQ ID NO: 10 Cas12j Protein SEQ ID NO: 11 gRNA RNA Sequence Listing <110> Shandong Shunfeng Biotechnology Co., Ltd. <120> A method for detecting hand, foot and mouth disease based on CRISPR technology <130> 11 <160> 11 <170> SIPOSequenceListing 1.0 <210> 1 <211> 41 <212> DNA <213> Artificial sequence <400> 1 tgtggaacaa cttccccggt gcatgcgctt tgatgcagag t 41 <210> 2 <211> 40 <212> DNA <213> Artificial sequence <400> 2 tatgtttgtg ccacctggag ccagtggcag tttgccatgc 40 <210> 3 <211> 18 <212> DNA <213> Artificial sequence <400> 3 gcgtaggaag gtggagct 18 <210> 4 <211> 18 <212> DNA <213> Artificial sequence <400> 4 ctggagggtc tgacagct 18 <210> 5 <211> 18 <212> DNA <213> Artificial sequence <400> 5 tgtgcacgca acaaaagt 18 <210> 6 <211> 19 <212> DNA <213> Artificial sequence <400> 6 aagccagatt caagggaat 19 <210> 7 <211> 1228 <212> PRT <213> Artificial sequence <400> 7 Met Ser Lys Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Lys Thr 1 5 10 15 Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile Asp 20 25 30 Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys 35 40 45 Gly Val Lys Lys Leu Leu Asp Arg Tyr Tyr Leu Ser Phe Ile Asn Asp 50 55 60 Val Leu His Ser Ile Lys Leu Lys Asn Leu Asn Asn Tyr Ile Ser Leu 65 70 75 80 Phe Arg Lys Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn 85 90 95 Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn 100 105 110 Glu Gly Tyr Lys Ser Leu Phe Lys Lys Asp Ile Ile Glu Thr Ile Leu 115 120 125 Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser Phe 130 135 140 Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn 145 150 155 160 Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile 165 170 175 Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys 180 185 190 Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu Lys 195 200 205 Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu Phe 210 215 220 Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile 225 230 235 240 Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn 245 250 255 Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys 260 265 270 Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu Ser 275 280 285 Phe Tyr Gly Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe 290 295 300 Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys 305 310 315 320 Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile 325 330 335 Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe 340 345 350 Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp 355 360 365 Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp 370 375 380 Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu 385 390 395 400 Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu 405 410 415 Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser 420 425 430 Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys 435 440 445 Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys 450 455 460 Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr 465 470 475 480 Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile 485,490,495 Leu Leu Lys Val Asp His With Tyr Asp With Arg Asn Tyr Val Thr 500 505 510 Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro 515,520,525 Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala 530 535 540 Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Leu Ala Ile Met Asp Lys 545 550 555 560 Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Val Asn Gly 565,570,575 Asn Tyr Glu Lys And Asn Tyr Lys Leu Pro Gly Pro Asn Lys Met 580,585,590 Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro 595,600,605 Serving Glu Asp With Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Gly 610 615 620 Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys 625 630 635 640 Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn 645,650,655 Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu 660,665,670 Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys 675,680,685 Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile 690,695,700 Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu His 705 710 715 720 Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln Ile 725 730 735 Arg Leu Ser Gly Gly Ala Glu Leu Phe Met Arg Arg Ala Ser Leu Lys 740 745 750 Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn Lys 755 760 765 Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val Tyr 770 775 780 Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro Ile 785 790 795 800 Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu Val 805 810 815 Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile Asp 820 825 830 Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly 835 840 845 Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn 850 855 860 Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu 865 870 875 880 Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile 885 890 895 Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys 900 905 910 Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn 915 920 925 Ser Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln 930 935 940 Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys 945 950 955 960 Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile 965 970 975 Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Thr Gln Asn Gly Phe 980 985 990 Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr 995 1000 1005 Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp Ser 1010 1015 1020 Lys Lys Phe Ile Ser Ser Phe Asp Arg Ile Met Tyr Val Pro Glu Glu 1025 1030 1035 1040 Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser Arg Thr Asp 1045 1050 1055 Only Asp Tyr Ile Lys Trp Leu Tyr Ser Tyr Gly Asn Arg Ile 1060 1065 1070 Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val Phe Asp Trp Glu Glu 1075 1080 1085 Val Cys Leu Thr Serves On Tyr Gly Ile 1090 1095 1100 Asn Tyr Gln Gln Gly Asp With Arg Ala Leu Leu Cys Gln Gln Ser Asp 1105 1110 1115 1120 Lys Ala Phe Tyr Ser Ser Phe Met Ala Leu Met Ser Leu Met Leu Gln 1125 1130 1135 Met Arg Asn Is Thr Gly Arg Thr Asp Val Asp Phe Leu Is Served 1140 1145 1150 Pro Val Lys Asn Ser Asp Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu 1155 1160 1165 Ala Gln Glu Asn Ala Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala 1170 1175 1180 Tyr Asn Ile Ala Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys 1185 1190 1195 1200 Ala Glu Asp Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys 1205 1210 1215 Glu Trp Leu Glu Tyr Ala Gln Thr Ser Val Lys His 1220 1225 <210> 8 <211> 1129 <212> PRT <213> artificial sequence <400> 8 Met Ala Val Lys Ser Ile Lys Val Lys Leu Arg Leu Asp Asp Met Pro 1 5 10 15 Glu Ile Arg Ala Gly Leu Trp Lys Leu His Lys Glu Val Asn Ala Gly 20 25 30 Val Arg Tyr Tyr Thr Glu Trp Leu Ser Leu Leu Arg Gln Glu Asn Leu 35 40 45 Tyr Arg Arg Ser Pro Asn Gly Asp Gly Glu Gln Glu Cys Asp Lys Thr 50 55 60 Ala Glu Glu Cys Lys Ala Glu Leu Leu Glu Arg Leu Arg Ala Arg Gln 65 70 75 80 Val Glu Asn Gly His Arg Gly Pro Ala Gly Ser Asp Asp Glu Leu Leu 85 90 95 Gln Leu Ala Arg Gln Leu Tyr Glu Leu Leu Val Pro Gln Ala Ile Gly 100 105 110 Ala Lys Gly Asp Ala Gln Gln Ile Ala Arg Lys Phe Leu Ser Pro Leu 115 120 125 Ala Asp Lys Asp Ala Val Gly Gly Leu Gly Ile Ala Lys Ala Gly Asn 130 135 140 Lys Pro Arg Trp Val Arg Met Arg Glu Ala Gly Glu Pro Gly Trp Glu 145 150 155 160 Glu Glu Lys Glu Lys Ala Glu Thr Arg Lys Ser Ala Asp Arg Thr Ala 165 170 175 Asp Val Leu Arg Ala Leu Ala Asp Phe Gly Leu Lys Pro Leu Met Arg 180 185 190 Val Tyr Thr Asp Ser Glu Met Ser Ser Val Glu Trp Lys Pro Leu Arg 195 200 205 Lys Gly Gln Ala Val Arg Thr Trp Asp Arg Asp Met Phe Gln Gln Ala 210 215 220 Ile Glu Arg Met Met Ser Trp Glu Ser Trp Asn Gln Arg Val Gly Gln 225 230 235 240 Glu Tyr Ala Lys Leu Val Glu Gln Lys Asn Arg Phe Glu Gln Lys Asn 245 250 255 Phe Val Gly Gln Glu His Leu Val His Leu Val Asn Gln Leu Gln Gln 260 265 270 Asp Met Lys Glu Ala Ser Pro Gly Leu Glu Ser Lys Glu Gln Thr Ala 275 280 285 His Tyr Val Thr Gly Arg Ala Leu Arg Gly Ser Asp Lys Val Phe Glu 290 295 300 Lys Trp Gly Lys Leu Ala Pro Asp Ala Pro Phe Asp Leu Tyr Asp Ala 305 310 315 320 Glu Ile Lys Asn Val Gln Arg Arg Asn Thr Arg Arg Phe Gly Ser His 325 330 335 Asp Leu Phe Ala Lys Leu Ala Glu Pro Glu Tyr Gln Ala Leu Trp Arg 340 345 350 Glu Asp Ala Ser Phe Leu Thr Arg Tyr Ala Val Tyr Asn Ser Ile Leu 355 360 365 Arg Lys Leu Asn His Ala Lys Met Phe Ala Thr Phe Thr Leu Pro Asp 370 375 380 Ala Thr Ala His Pro Ile Trp Thr Arg Phe Asp Lys Leu Gly Gly Asn 385 390 395 400 Leu His Gln Tyr Thr Phe Leu Phe Asn Glu Phe Gly Glu Arg Arg His 405 410 415 Ala Ile Arg Phe His Lys Leu Leu Lys Val Glu Asn Gly Val Ala Arg 420 425 430 Glu Val Asp Asp Val Thr Val Pro Ile Ser Met Ser Glu Gln Leu Asp 435 440 445 Asn Leu Leu Pro Arg Asp Pro Asn Glu Pro Ile Ala Leu Tyr Phe Arg 450 455 460 Asp Tyr Gly Ala Glu Gln His Phe Thr Gly Glu Phe Gly Gly Ala Lys 465 470 475 480 Ile Gln Cys Arg Arg Asp Gln Leu Ala His Met His Arg Arg Arg Gly 485 490 495 Ala Arg Asp Val Tyr Leu Asn Val Ser Val Arg Val Gln Ser Gln Ser 500 505 510 Glu Ala Arg Gly Glu Arg Arg Pro Pro Tyr Ala Ala Val Phe Arg Leu 515 520 525 Val Gly Asp Asn His Arg Ala Phe Val His Phe Asp Lys Leu Ser Asp 530 535 540 Tyr Leu Ala Glu His Pro Asp Asp Gly Lys Leu Gly Ser Glu Gly Leu 545 550 555 560 Leu Ser Gly Leu Arg Val Met Ser Val Asp Leu Gly Leu Arg Thr Ser 565 570 575 Ala Ser Ile Ser Val Phe Arg Val Ala Arg Lys Asp Glu Leu Lys Pro 580 585 590 Asn Ser Lys Gly Arg Val Pro Phe Phe Phe Pro Ile Lys Gly Asn Asp 595 600 605 Asn Leu Val Ala Val His Glu Arg Ser Gln Leu Leu Lys Leu Pro Gly 610 615 620 Glu Thr Glu Ser Lys Asp Leu Arg Ala Ile Arg Glu Glu Arg Gln Arg 625 630 635 640 Thr Leu Arg Gln Leu Arg Thr Gln Leu Ala Tyr Leu Arg Leu Leu Val 645 650 655 Arg Cys Gly Ser Glu Asp Val Gly Arg Arg Glu Arg Ser Trp Ala Lys 660 665 670 Leu Ile Glu Gln Pro Val Asp Ala Ala Asn His Met Thr Pro Asp Trp 675 680 685 Arg Glu Ala Phe Glu Asn Glu Leu Gln Lys Leu Lys Ser Leu His Gly 690 695 700 Ile Cys Ser Asp Lys Glu Trp Met Asp Ala Val Tyr Glu Ser Val Arg 705 710 715 720 Arg Val Trp Arg His Met Gly Lys Gln Val Arg Asp Trp Arg Lys Asp 725 730 735 Val Arg Ser Gly Glu Arg Pro Lys Ile Arg Gly Tyr Ala Lys Asp Val 740 745 750 Val Gly Gly Asn Ser Ile Glu Gln Ile Glu Tyr Leu Glu Arg Gln Tyr 755 760 765 Lys Phe Leu Lys Ser Trp Ser Phe Phe Gly Lys Val Ser Gly Gln Val 770 775 780 Ile Arg Ala Glu Lys Gly Ser Arg Phe Ala Ile Thr Leu Arg Glu His 785 790 795 800 Ile Asp His Ala Lys Glu Asp Arg Leu Lys Lys Leu Ala Asp Arg Ile 805 810 815 Ile Met Glu Ala Leu Gly Tyr Val Tyr Ala Leu Asp Glu Arg Gly Lys 820 825 830 Gly Lys Trp Val Ala Lys Tyr Pro Pro Cys Gln Leu Ile Leu Leu Glu 835 840 845 Glu Leu Ser Glu Tyr Gln Phe Asn Asn Asp Arg Pro Pro Ser Glu Asn 850 855 860 Asn Gln Leu Met Gln Trp Ser His Arg Gly Val Phe Gln Glu Leu Ile 865 870 875 880 Asn Gln Ala Gln Val His Asp Leu Leu Val Gly Thr Met Tyr Ala Ala 885 890 895 Phe Ser Ser Arg Phe Asp Ala Arg Thr Gly Ala Pro Gly Ile Arg Cys 900 905 910 Arg Arg Val Pro Ala Arg Cys Thr Gln Glu His Asn Pro Glu Pro Phe 915 920 925 Pro Trp Trp Leu Asn Lys Phe Val Val Glu His Thr Leu Asp Ala Cys 930 935 940 Pro Leu Arg Ala Asp Asp Leu Ile Pro Thr Gly Glu Gly Glu Ile Phe 945 950 955 960 Val Ser Pro Phe Ser Ala Glu Glu Gly Asp Phe His Gln Ile His Ala 965 970 975 Asp Leu Asn Ala Ala Gln Asn Leu Gln Gln Arg Leu Trp Ser Asp Phe 980 985 990 Asp Ile Ser Gln Ile Arg Leu Arg Cys Asp Trp Gly Glu Val Asp Gly 995 1000 1005 Glu Leu Val Leu Ile Pro Arg Leu Thr Gly Lys Arg Thr Ala Asp Ser 1010 1015 1020 Tyr Ser Asn Lys Val Phe Tyr Thr Asn Thr Gly Val Thr Tyr Tyr Glu 1025 1030 1035 1040 Arg Glu Arg Gly Lys Lys Arg Arg Lys Val Phe Ala Gln Glu Lys Leu 1045 1050 1055 Ser Glu Glu Glu Ala Glu Leu Leu Val Glu Ala Asp Glu Ala Arg Glu 1060 1065 1070 Lys Ser Val Val Leu Met Arg Asp Pro Ser Gly Ile Ile Asn Arg Gly 1075 1080 1085 Asn Trp Thr Arg Gln Lys Glu Phe Trp Ser Met Val Asn Gln Arg Ile 1090 1095 1100 Glu Gly Tyr Leu Val Lys Gln Ile Arg Ser Arg Val Pro Leu Gln Asp 1105 1110 1115 1120 Ser Ala Cys Glu Asn Thr Gly Asp Ile 1125 <210> 9 <211> 1045 <212> PRT <213> artificial sequence <400> 9 Met Lys Lys Val Glu Val Ser Arg Pro Tyr Gln Ser Leu Leu Leu Pro 1 5 10 15 Asn His Arg Lys Phe Lys Tyr Leu Asp Glu Thr Trp Asn Ala Tyr Lys 20 25 30 Ser Val Lys Ser Leu Leu His Arg Phe Leu Val Cys Ala Tyr Gly Ala 35 40 45 Val Pro Phe Asn Lys Phe Val Glu Val Val Glu Lys Val Asp Asn Asp 50 55 60 Gln Leu Val Leu Ala Phe Ala Val Arg Leu Phe Arg Leu Val Pro Val 65 70 75 80 Glu Ser Thr Ser Phe Ala Lys Val Asp Lys Ala Asn Leu Ala Lys Ser 85 90 95 Leu Ala Asn His Leu Pro Val Gly Thr Ala Ile Pro Ala Asn Val Gln 100 105 110 Ser Tyr Phe Asp Ser Asn Phe Asp Pro Lys Lys Tyr Met Trp Ile Asp 115 120 125 Cys Ala Trp Glu Ala Asp Arg Leu Ala Arg Glu Met Gly Leu Ser Ala 130 135 140 Ser Gln Phe Ser Glu Tyr Ala Thr Thr Met Leu Trp Glu Asp Trp Leu 145 150 155 160 Pro Leu Asn Lys Asp Asp Val Asn Gly Trp Gly Ser Val Ser Gly Leu 165 170 175 Phe Gly Glu Gly Lys Lys Glu Asp Arg Gln Gln Lys Val Lys Met Leu 180 185 190 Asn Asn Leu Leu Asn Gly Ile Lys Lys Asn Pro Pro Lys Asp Tyr Thr 195 200 205 Gln Tyr Leu Lys Ile Leu Leu Asn Ala Phe Asp Ala Lys Ser His Lys 210 215 220 Glu Ala Val Lys Asn Tyr Lys Gly Asp Ser Thr Gly Arg Thr Ala Ser 225 230 235 240 Tyr Leu Ser Glu Lys Ser Gly Glu Ile Thr Glu Leu Met Leu Glu Gln 245 250 255 Leu Met Ser Asn Ile Gln Arg Asp Ile Gly Asp Lys Gln Lys Glu Ile 260 265 270 Ser Leu Pro Lys Lys Asp Val Val Lys Lys Tyr Leu Glu Ser Glu Ser 275 280 285 Gly Val Pro Tyr Asp Gln Asn Leu Trp Ser Gln Ala Tyr Arg Asn Ala 290 295 300 Ala Ser Ser Ile Lys Lys Thr Asp Thr Arg Asn Phe Asn Ser Thr Leu 305 310 315 320 Glu Lys Phe Lys Asn Glu Val Glu Leu Arg Gly Leu Leu Ser Glu Gly 325 330 335 Asp Asp Val Glu Ile Leu Arg Ser Lys Phe Phe Ser Ser Glu Phe His 340 345 350 Lys Thr Pro Asp Lys Phe Val Ile Lys Pro Glu His Ile Gly Phe Asn 355 360 365 Asn Lys Tyr Asn Val Val Ala Glu Leu Tyr Lys Leu Lys Ala Glu Ala 370 375 380 Thr Asp Phe Glu Ser Ala Phe Ala Thr Val Lys Asp Glu Phe Glu Glu 385 390 395 400 Lys Gly Ile Lys His Pro Ile Lys Asn Ile Leu Glu Tyr Ile Trp Asn 405 410 415 Asn Glu Val Pro Val Glu Lys Trp Gly Arg Val Ala Arg Phe Asn Gln 420 425 430 Ser Glu Glu Lys Leu Leu Arg Ile Lys Ala Asn Pro Thr Val Glu Cys 435 440 445 Asn Gln Gly Met Thr Phe Gly Asn Ser Ala Met Val Gly Glu Val Leu 450 455 460 Arg Ser Asn Tyr Val Ser Lys Lys Gly Ala Leu Val Ser Gly Glu His 465 470 475 480 Gly Gly Arg Leu Ile Gly Gln Asn Asn Met Ile Trp Leu Glu Met Arg 485 490 495 Leu Leu Asn Lys Gly Lys Trp Glu Thr His His Val Pro Thr His Asn 500 505 510 Met Lys Phe Phe Glu Glu Val His Ala Tyr Asn Pro Ser Leu Ala Asp 515 520 525 Ser Val Asn Val Arg Asn Arg Leu Tyr Arg Ser Glu Asp Tyr Thr Gln 530 535 540 Leu Pro Ser Ser Ile Thr Asp Gly Leu Lys Gly Asn Pro Lys Ala Lys 545 550 555 560 Leu Leu Lys Arg Gln His Cys Ala Leu Asn Asn Met Thr Ala Asn Val 565 570 575 Leu Asn Pro Lys Leu Ser Phe Thr Ile Asn Lys Lys Asn Asp Asp Tyr 580 585 590 Thr Val Ile Ile Val His Ser Val Glu Val Ser Lys Pro Arg Arg Glu 595 600 605 Val Leu Val Gly Asp Tyr Leu Val Gly Met Asp Gln Asn Gln Thr Ala 610 615 620 Ser Asn Thr Tyr Ala Val Met Gln Val Val Lys Pro Lys Ser Thr Asp 625 630 635 640 Ala Ile Pro Phe Arg Asn Met Trp Val Arg Phe Val Glu Ser Gly Ser 645 650 655 Ile Glu Ser Arg Thr Leu Asn Ser Arg Gly Glu Tyr Val Asp Gln Leu 660 665 670 Asn His Asp Gly Val Asp Leu Phe Glu Ile Gly Asp Thr Glu Trp Val 675 680 685 Asp Ser Ala Arg Lys Phe Phe Asn Lys Leu Gly Val Lys His Lys Asp 690 695 700 Gly Thr Leu Val Asp Leu Ser Thr Ala Pro Arg Lys Ala Tyr Ala Phe 705 710 715 720 Asn Asn Phe Tyr Phe Lys Thr Met Leu Asn His Leu Arg Ser Asn Glu 725 730 735 Val Asp Leu Thr Leu Leu Arg Asn Glu Ile Leu Arg Val Ala Asn Gly 740 745 750 Arg Phe Ser Pro Met Arg Leu Gly Ser Leu Ser Trp Thr Thr Leu Lys 755 760 765 Ala Leu Gly Ser Phe Lys Ser Leu Val Leu Ser Tyr Phe Asp Arg Leu 770 775 780 Gly Ala Lys Glu Met Val Asp Lys Glu Ala Lys Asp Lys Ser Leu Phe 785 790 795 800 Asp Leu Leu Val Ala Ile Asn Asn Lys Arg Ser Asn Lys Arg Glu Glu 805 810 815 Arg Thr Ser Arg Ile Ala Ser Ser Leu Met Thr Val Ala Gln Lys Tyr 820 825 830 Lys Val Asp Asn Ala Val Val His Val Val Val Glu Gly Asn Leu Ser 835 840 845 Ser Thr Asp Arg Ser Ala Ser Lys Ala His Asn Arg Asn Thr Met Asp 850 855 860 Trp Cys Ser Arg Ala Val Val Lys Lys Leu Glu Asp Met Cys Asn Leu 865 870 875 880 Tyr Gly Phe Asn Ile Lys Gly Val Pro Ala Phe Tyr Thr Ser His Gln 885 890 895 Asp Pro Leu Val His Arg Ala Asp Tyr Asp Asp Pro Lys Pro Ala Leu 900 905 910 Arg Cys Arg Tyr Ser Ser Tyr Ser Arg Ala Asp Phe Ser Lys Trp Gly 915 920 925 Gln Asn Ala Leu Ala Ala Val Val Arg Trp Ala Ser Asn Lys Lys Ser 930 935 940 Asn Thr Cys Tyr Lys Val Gly Ala Val Glu Phe Leu Lys Gln His Gly 945 950 955 960 Leu Phe Ala Asp Lys Lys Leu Thr Val Glu Gln Phe Leu Ser Lys Val 965 970 975 Lys Asp Glu Glu Ile Leu Ile Pro Arg Arg Gly Gly Arg Val Phe Leu 980 985 990 Thr Thr His Arg Leu Leu Ala Glu Ser Thr Phe Val Tyr Leu Asn Gly 995 1000 1005 Val Lys Tyr His Ser Cys Asn Ala Asp Glu Val Ala Ala Val Asn Ile 1010 1015 1020 Cys Leu Asn Asp Trp Val Ile Pro Cys Lys Lys Lys Met Lys Glu Glu 1025 1030 1035 1040 Ser Ser Ala Ser Gly 1045 <210> 10 <211> 908 <212> PRT <213> artificial sequence <400> 10 Met Pro Ser Tyr Lys Ser Ser Arg Val Leu Val Arg Asp Val Pro Glu 1 5 10 15 Glu Leu Val Asp His Tyr Glu Arg Ser His Arg Val Ala Ala Phe Phe 20 25 30 Met Arg Leu Leu Leu Ala Met Arg Arg Glu Pro Tyr Ser Leu Arg Met 35 40 45 Arg Asp Gly Thr Glu Arg Glu Val Asp Leu Asp Glu Thr Asp Asp Phe 50 55 60 Leu Arg Ser Ala Gly Cys Glu Glu Pro Asp Ala Val Ser Asp Asp Leu 65 70 75 80 Arg Ser Phe Ala Leu Ala Val Leu His Gln Asp Asn Pro Lys Lys Arg 85 90 95 Ala Phe Leu Glu Ser Glu Asn Cys Val Ser Ile Leu Cys Leu Glu Lys 100 105 110 Ser Ala Ser Gly Thr Arg Tyr Tyr Lys Arg Pro Gly Tyr Gln Leu Leu 115 120 125 Lys Lys Ala Ile Glu Glu Glu Trp Gly Trp Asp Lys Phe Glu Ala Ser 130 135 140 Leu Leu Asp Glu Arg Thr Gly Glu Val Ala Glu Lys Phe Ala Ala Leu 145 150 155 160 Ser Met Glu Asp Trp Arg Arg Phe Phe Ala Ala Arg Asp Pro Asp Asp 165 170 175 Leu Gly Arg Glu Leu Leu Lys Thr Asp Thr Arg Glu Gly Met Ala Ala 180 185 190 Ala Leu Arg Leu Arg Glu Arg Gly Val Phe Pro Val Ser Val Pro Glu 195 200 205 His Leu Asp Leu Asp Ser Leu Lys Ala Ala Met Ala Ser Ala Ala Glu 210 215 220 Arg Leu Lys Ser Trp Leu Ala Cys Asn Gln Arg Ala Val Asp Glu Lys 225 230 235 240 Ser Glu Leu Arg Lys Arg Phe Glu Glu Ala Leu Asp Gly Val Asp Pro 245 250 255 Glu Lys Tyr Ala Leu Phe Glu Lys Phe Ala Ala Glu Leu Gln Gln Ala 260 265 270 Asp Tyr Asn Val Thr Lys Lys Leu Val Leu Ala Val Ser Ala Lys Phe 275 280 285 Pro Ala Thr Glu Pro Ser Glu Phe Lys Arg Gly Val Glu Ile Leu Lys 290 295 300 Glu Asp Gly Tyr Lys Pro Leu Trp Glu Asp Phe Arg Glu Leu Gly Phe 305 310 315 320 Val Tyr Leu Ala Glu Arg Lys Trp Glu Arg Arg Arg Gly Gly Ala Ala 325 330 335 Val Thr Leu Cys Asp Ala Asp Asp Ser Pro Ile Lys Val Arg Phe Gly 340 345 350 Leu Thr Gly Arg Gly Arg Lys Phe Val Leu Ser Ala Ala Gly Ser Arg 355 360 365 Phe Leu Ile Thr Val Lys Leu Pro Cys Gly Asp Val Gly Leu Thr Ala 370 375 380 Val Pro Ser Arg Tyr Phe Trp Asn Pro Ser Val Gly Arg Thr Thr Ser 385 390 395 400 Asn Ser Phe Arg Ile Glu Phe Thr Lys Arg Thr Thr Glu Asn Arg Arg 405 410 415 Tyr Val Gly Glu Val Lys Glu Ile Gly Leu Val Arg Gln Arg Gly Arg 420 425 430 Tyr Tyr Phe Phe Ile Asp Tyr Asn Phe Asp Pro Glu Glu Val Ser Asp 435 440 445 Glu Thr Lys Val Gly Arg Ala Phe Phe Arg Ala Pro Leu Asn Glu Ser 450 455 460 Arg Pro Lys Pro Lys Asp Lys Leu Thr Val Met Gly Ile Asp Leu Gly 465 470 475 480 Ile Asn Pro Ala Phe Ala Phe Ala Val Cys Thr Leu Gly Glu Cys Gln 485 490 495 Asp Gly Ile Arg Ser Pro Val Ala Lys Met Glu Asp Val Ser Phe Asp 500 505 510 Ser Thr Gly Leu Arg Gly Gly Ile Gly Ser Gln Lys Leu His Arg Glu 515,520,525 Met His Asn Leu Ser Asp Arg Cys Phe Tyr Gly Ala Arg Tyr Ile Arg 530 535 540 The Ser of Lys Lys The Arg Asp Arg Gly Ala is the Asp Ile Glu Ala 545 550 555 560 Arg Leu Leu Glu Glu Lys Tyr Ile Pro Gly Phe Arg Ile Val His Ile 565,570,575 Glu Asp Ala Asp Glu Arg Arg Arg Thr Will Gly Arg Thr Will Lys Glu 580,585,590 With Gln Glu Tyr Lys Arg and His Gln Phe Tyr Leu Arg Tyr 595,600,605 His Three Served Lys Arg Asp Arg Thr Glu Leu Ile Served Ala Glu Tyr Phe 610 615 620 Arg Met Leu Phe Leu Val Lys Ser Trp 625 630 635 640 Asn Arg Tyr His Trp Thr Thr Gly Asp Arg Glu Arg Arg Gly Gly Asn 645,650,655 Pro Asp Glu Leu Lys Ser Tyr Val Arg Tyr Tyr Asn Asn Leu Arg Met 660,665,670 Asp Thr With Lys Lys Lew With Thr Cys Ala Ile Val Arg Thr With Lys Glu 675 680 685 His Gly Ala Thr Leu Val Ala Met Glu Asn Ile Gln Arg Val Asp Arg 690 695 700 Asp Asp Glu Val Lys Arg Arg Lys Glu Asn Ser Leu Leu Ser Leu Trp 705 710 715 720 Ala Pro Gly Met Val Leu Glu Arg Val Glu Gln Glu Leu Lys Asn Glu 725 730 735 Gly Ile Leu Ala Trp Glu Val Asp Pro Arg His Thr Ser Gln Thr Ser 740 745 750 Cys Ile Thr Asp Glu Phe Gly Tyr Arg Ser Leu Val Ala Lys Asp Thr 755 760 765 Phe Tyr Phe Glu Gln Asp Arg Lys Ile His Arg Ile Asp Ala Asp Val 770 775 780 Asn Ala Ala Ile Asn Ile Ala Arg Arg Phe Leu Thr Arg Tyr Arg Ser 785 790 795 800 Leu Thr Gln Leu Trp Ala Ser Leu Leu Asp Asp Gly Arg Tyr Leu Val 805 810 815 Asn Val Thr Arg Gln His Glu Arg Ala Tyr Leu Glu Leu Gln Thr Gly 820 825 830 Ala Pro Ala Ala Thr Leu Asn Pro Thr Ala Glu Ala Ser Tyr Glu Leu 835 840 845 Val Gly Leu Ser Pro Glu Glu Glu Glu Leu Ala Gln Thr Arg Ile Lys 850 855 860 Arg Lys Lys Arg Glu Pro Phe Tyr Arg His Glu Gly Val Trp Leu Thr 865 870 875 880 Arg Glu Lys His Arg Glu Gln Val His Glu Leu Arg Asn Gln Val Leu 885 890 895 Ala Leu Gly Asn Ala Lys Ile Pro Glu Ile Arg Thr 900 905 <210> 11 <211> 47 <212> RNA <213> Artificial Sequence <400> 11 agagaaugug ugcauaguca cacaugcaga guucacuuuu guugcgu 47 Description of the Drawings

[0109] Figure 1. Results of hand, foot and mouth disease detection using three groups of LAMP primers: Lanes 1-4 are the amplification results of the first group of primers at sample concentrations of 20fM, 200aM, 20aM, and 2aM, respectively; Lane 5 is the positive control of the first group of primers; Lane 6 is the negative control of the first group of primers; the first group of primers cannot amplify the target band under the above conditions; Lanes 7-10 are the amplification results of the second group of primers at sample concentrations of 20fM, 200aM, 20aM, and 2aM, respectively; Lane 11 is the positive control of the second group of primers; Lane 20 is the negative control of the second group of primers; Lane 21 is the positive control of the second group of primers; Lane 22 is the negative control of the first group of primers; Lane 23 is the positive control of the first group of primers; Lane 24 is the negative control of the first group of primers; Lane 25 is the positive control of the first group of primers; Lane 26 is the negative control of the first group of primers; Lane 27 is the positive control of the first group of primers; Lane 28 is the negative control of the first group of primers; Lane 29 is the positive control of the first group of primers; Lane 30 is the negative control of the first group of primers; Lane 31 is the positive control of the first group of primers; Lane 32 is the negative control of the first group of primers; Lane 33 is the positive control of the first group of primers; Lane 34 is the negative control of the first group of primers; Lane 35 is the positive control of the first group of primers; Lane 36 is the negative control of the first group of primers; Lane 37 is the positive control of the first group of primers; Lane 38 is the negative control of the first group of primers; Lane 39 is the positive control of the first group of primers; Lane 40 Lane 12 is the negative control of the second set of primers. The second set of primers could not amplify the target band under the above conditions; Lanes 13-16 are the amplification results of the third set of primers when the sample concentration is 20fM, 200aM, 20aM, and 2aM, respectively; Lane 17 is the positive control of the third set of primers; Lane 18 is the negative control of the third set of primers. The third set of primers can amplify the target band when the sample concentration is 20fM, 200aM, 20aM, and 2aM, and the positive control has bands, while the negative control has no bands.

[0110] Figure 2 .The results of hand, foot and mouth disease detection using three different concentrations of the third group of LAMP primers: lanes 1-4 are the results of 22 minutes of amplification reaction at sample concentrations of 200aM, 20aM, 2aM and negative control, respectively. The target bands can be amplified when the substrate concentrations are 200aM and 20aM, while there are no bands in 2aM and negative control; lanes 5-8 are the results of 24 minutes of amplification reaction at sample concentrations of 200aM, 20aM, 2aM and negative control, respectively. The target bands can be amplified with all three substrate concentrations, while there are no bands in the negative control; lanes 9-12 are the results of 26 minutes of amplification reaction at sample concentrations of 200aM, 20aM, 2aM and negative control, respectively. The target bands can be amplified with all three substrate concentrations, while there are no bands in the negative control.

[0111] Figure 3 .After amplification using the third set of LAMP primers, the results of hand, foot and mouth disease detection using Cas enzyme fluorescence: different sample concentrations can quickly report fluorescence.

[0112] Figure 4 .After amplification with the third set of LAMP primers, the test strips tested hand, foot and mouth disease. The test strips tested positive when the sample concentrations were 20fM, 200aM, and 20aM, and the negative control test strips tested negative. Implementation

[0113] The present invention is further described below in conjunction with the embodiments. The following description is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change it into an equivalent embodiment with equivalent changes. Any simple modification or equivalent change made to the following embodiments based on the technical essence of the present invention without departing from the content of the present invention falls within the protection scope of the present invention.

[0114] The technical solution of the present invention is based on the following principles: the nucleic acid of the sample to be tested is obtained. For example, the target nucleic acid can be obtained by an amplification method, and the gRNA that can be paired with the target nucleic acid is used to guide the Cas protein to recognize and bind to the target nucleic acid; then, the Cas protein stimulates the cleavage activity of single-stranded DNA, single-stranded RNA or single-stranded DNA-RNA hybrid, thereby cutting the single-stranded nucleic acid detector in the system; a fluorescent group and a quenching group are respectively set at both ends of the single-stranded nucleic acid detector, and if the single-stranded nucleic acid detector is cut, fluorescence will be stimulated; in other embodiments, the two ends of the single-stranded nucleic acid detector can also be set as a mark that can be detected by colloidal gold.

[0115] Example 1: Detection of hand, foot and mouth disease (enterovirus 71, EV71) using three sets of LAMP primers

[0116] LAMP amplified the hand, foot and mouth disease (enterovirus 71, EV71) gene, and three sets of LAMP primers were designed, and the sequences are shown in Table 1.

[0117] Table 1. Three sets of LAMP primers for amplifying EV71 virus

[0118]

[0119] The samples were added according to the following system and reacted at 65°C for 30 minutes. The LAMP amplification products were run on a gel. The results of the three sets of LAMP primers for amplifying the hand, foot and mouth disease virus were as follows: Figure 1 As shown, the first and second primer groups could not amplify the target bands when the sample concentrations were 20fM, 200aM, 20aM, and 2aM, while the third primer group could amplify the target bands when the sample concentrations were 20fM, 200aM, 20aM, and 2aM.

[0120]

[0121] Example 2: Detection of hand, foot and mouth disease using three different concentrations of the third set of LAMP primers

[0122] The reaction system of Example 1 was used to perform the reaction at a gradient sample concentration of 200aM, 20aM, and 2aM at 65°C, and the reaction results were taken for 22min, 24min, and 26min, respectively. The gel electrophoresis diagram is shown in FIG. Figure 2 As shown, when the sample concentration is 200aM and 20aM, the target band can be amplified after 22min, 24min, and 26min of reaction; when the sample concentration is 2aM, the target band can be amplified after 24min and 26min of reaction.

[0123] Example 3: After amplification using the third set of LAMP primers, fluorescence detection using Cas12i

[0124] The reaction system of Example 1 was used to react at gradient sample concentrations of 200aM, 20aM, and 2aM at 65° C. The reaction results for 24 minutes were used for CRISPR detection.

[0125] Cas12i (SEQ ID NO: 9), gRNA (SEQ ID NO: 11, LAMP product and single-stranded nucleic acid detector Reporter (5'-FAM-TTGTT-3'BHQ) were added to the detection system respectively; the final concentration of Cas12i was 100nM, the final concentration of gRNA was 50nM, the LAMP product was 1ul, and the final concentration of Reporter (5'-FAM-TTGTT-3'BHQ) was 500nM.

[0126] Test results such as Figure 3 As shown, the amplification products at sample concentrations of 200aM, 20aM, and 2aM can all detect obvious fluorescence signals within 10 minutes.

[0127] Example 4: Results of the test strip for hand, foot and mouth disease after amplification using the third set of LAMP primers

[0128] The reaction system of Example 1 was used to react at gradient sample concentrations of 20 fM, 200 aM, and 20 aM at 65° C. The reaction results for 30 min were used for CRISPR detection.

[0129] The experimental system is as follows: the final concentration of Cas12i is 100nM, the final concentration of gRNA is 50nM, the LAMP product is 1ul, the final concentration of the single-stranded nucleic acid detector Reporter (5'-FAM-TTGTT-3'BIO) is 500nM, and the total system is a 20ul reaction system.

[0130] The results of the color development of the nanogold test strip are as follows Figure 4As shown, after reacting at 42°C for 3 minutes, a test strip was inserted into the reaction system, and the detection results of the amplified products at sample concentrations of 20fM, 200aM, and 20aM were all positive.

[0131] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for detecting a target nucleic acid in a sample based on CRISPR technology, the method being a method for non-disease diagnosis and treatment purposes, the method comprising contacting the sample with a V-type CRISPR / CAS effector protein, a gRNA and a single-stranded nucleic acid detector; The gRNA includes a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the target nucleic acid; a detectable signal generated by the CRISPR / CAS effector protein cutting the single-stranded nucleic acid detector is detected to detect the target nucleic acid; the target nucleic acid is a viral nucleic acid, the viral nucleic acid is a nucleic acid derived from an enterovirus, the enterovirus is enterovirus 71, and the virus can cause hand, foot and mouth disease, the nucleotide sequence of the gRNA is shown in SEQ ID NO: 11, the V-type Cas protein is Cas12i, and the amino acid sequence of the Cas protein is shown in SEQ ID NO: 9; The method further comprises the step of obtaining an amplification product from the sample to be tested, wherein the amplification product is obtained by amplifying the sample to be tested using a LAMP primer set, and the nucleotide sequence of the LAMP primer set is shown in SEQ ID NO: 1-6.

2. The method according to claim 1, characterized in that The detectable signal is detected by: sensor-based detection, gold nanoparticle-based detection, fluorescence polarization, colloidal phase transition / dispersion, electrochemical detection, and semiconductor-based detection.

3. The method according to claim 1, characterized in that The detectable signal is achieved by vision-based detection.

4. The method according to claim 3, characterized in that The vision-based detection includes color detection.